Diabetic Retinopathy Market by Type (Proliferative Diabetic Retinopathy, Diabetic Macular Edema (DME)), and Treatment Type (Anti VEGF Drug, Steroid Implants, Laser Surgeries, and Vitrectomy): Global Opportunity Analysis and Industry Forecast, 2020–2030
The global diabetic retinopathy market was valued at $3,086.00 million in 2020, and is projected to reach $10,785.50 million by 2030, registering a CAGR of 13.7% from 2021 to 2030.
Diabetic retinopathy is blood vessel damage in the retina that happens as a result of diabetes. Diabetic retinopathy can cause a range of symptoms, including blurred vision, difficulty seeing colors, and eye floaters. Without treatment, it can cause vision loss. Diabetic retinopathy is the leading cause of new cases of blindness in adults, as well as the most common cause of vision loss for people with diabetes. People may not have any early symptoms of diabetic retinopathy.
The diabetic retinopathy market has witnessed tremendous growth owing to technological advancements in the ophthalmic surgical and diagnostic instruments. Moreover, optical coherence tomography and other technologically upgraded devices utilized in diagnosis provide superior quality cross-sectional images that allow doctor to make better decisions. In addition, surgical instruments have enhanced precision that improves the surgery success rates. Thus, availability of such upgraded ophthalmic devices and instruments have facilitated the diagnostic and surgical procedures that positively impact the industry growth. However, complications and adverse reactions associated with the medications prescribed for minimizing the impact of diabetic retinopathy may hamper the industry growth to some extent.
The Diabetic Retinopathy market in this report is studied on the basis of type, treatment type, and region. On the basis of type, the market is divided by proliferative diabetic retinopathy and diabetic macular edema (DME). On the basis of treatment type, the market is classified into anti VEGF drug, steroid implants, laser surgeries, and vitrectomy. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Increase in the geriatric populations, rise in focus and awareness of early diagnosis in order to control the growth of the disease, surge in prevalence of diabetes, and growth in incidence of blindness due to diabetes drive the growth of the market. However, this growth is limited by dearth of skilled ophthalmologists and extended approval time for drugs. Conversely, emergence of combined therapies for treatment of diabetic macular edema and the emerging markets of Asia-Pacific and LAMEA are expected to provide several opportunities for market growth during the forecast period.
Region wise, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2020, owing to high prevalence of DR in this region, coupled with well-established infrastructure and increasing initiatives by the government to create awareness that would help people undergo screening for DR. However, Asia-Pacific is expected to witness considerable market growth during the forecast period, due to high population base, high disposable incomes, and improvement in patient awareness about the treatment of diabetic retinopathy.
The major players operating in the global Diabetic Retinopathy market are Alimera Science, Inc., Abbvie, Inc., Ampio Pharmaceuticals, Inc., Bayer AG, Kowa Co., Ltd., Novartis, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., F-Hoffmann-La Roche Ltd, Valeant Pharmaceuticals International, Inc. (Bausch Health Companies Inc.). These players adopted product launch, collaboration, and merger & acquisition as their key developmental strategies.
KEY BENEFITS FOR STAKEHOLDERS
The report provides in-depth analysis of the global diabetic retinopathy market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global diabetic retinopathy market growth.
KEY MARKET SEGMENTS
By Type
Proliferative Diabetic Retinopathy
Diabetic Macular Edema (DME)
By Treatment Type
Anti VEGF Drug
Steroid Implants
Laser Surgeries
Vitrectomy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
List of key players profiled in the report:
Alimera Science, Inc.
Abbvie, Inc.
Ampio Pharmaceuticals, Inc.
Bayer AG
Kowa Co., Ltd.
Novartis
Pfizer, Inc.
Regeneron Pharmaceuticals, Inc.
F-Hoffmann-La Roche Ltd.
Valeant Pharmaceuticals International, Inc. (Bausch Health Companies Inc.)
- CHAPTER 1:INTRODUCTION
- 1.1.Report Description
- 1.2.Key Market Segments
- 1.3.Key Benefits
- 1.4.Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.CXO Perspective
- CHAPTER 3:MARKET LANDSCAPE
- 3.1.Market Definition and Scope
- 3.2.Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3.Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4.Market Share Analysis/Top Player Positioning
- 3.4.1. Market Share Analysis/Top Player Positioning 2020
- 3.5.Market Dynamics
- 3.5.1. Drivers
- 3.5.2. Restraints
- 3.5.3. Opportunities
- 3.6.COVID-19 Impact Analysis
- CHAPTER 4:DIABETIC RETINOPATHY MARKET, BY TYPE
- 4.1.Market Overview
- 4.1.1Market Size and Forecast, By Type
- 4.2. Proliferative Diabetic Retinopathy
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Diabetic Macular Edema (DME)
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- CHAPTER 5:DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE
- 5.1.Market Overview
- 5.1.1Market Size and Forecast, By Treatment Type
- 5.2. Anti VEGF Drug
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Steroid Implants
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Laser Surgeries
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
- 5.5. Vitrectomy
- 5.5.1. Key Market Trends, Growth Factors and Opportunities
- 5.5.2. Market Size and Forecast, By Region
- 5.5.3. Market Share Analysis, By Country
- CHAPTER 6:DIABETIC RETINOPATHY MARKET, BY REGION
- 6.1.Market Overview
- 6.1.1Market Size and Forecast, By Region
- 6.2.North America
- 6.2.1. Key Market Trends and Opportunities
- 6.2.2. Market Size and Forecast, By Type
- 6.2.3. Market Size and Forecast, By Treatment Type
- 6.2.4. Market Size and Forecast, By Country
- 6.2.5. United States Diabetic Retinopathy Market
- 6.2.5.1. Market Size and Forecast, By Type
- 6.2.5.2. Market Size and Forecast, By Treatment Type
- 6.2.6. Canada Diabetic Retinopathy Market
- 6.2.6.1. Market Size and Forecast, By Type
- 6.2.6.2. Market Size and Forecast, By Treatment Type
- 6.2.7. Mexico Diabetic Retinopathy Market
- 6.2.7.1. Market Size and Forecast, By Type
- 6.2.7.2. Market Size and Forecast, By Treatment Type
- 6.3.Europe
- 6.3.1. Key Market Trends and Opportunities
- 6.3.2. Market Size and Forecast, By Type
- 6.3.3. Market Size and Forecast, By Treatment Type
- 6.3.4. Market Size and Forecast, By Country
- 6.3.5. France Diabetic Retinopathy Market
- 6.3.5.1. Market Size and Forecast, By Type
- 6.3.5.2. Market Size and Forecast, By Treatment Type
- 6.3.6. Germany Diabetic Retinopathy Market
- 6.3.6.1. Market Size and Forecast, By Type
- 6.3.6.2. Market Size and Forecast, By Treatment Type
- 6.3.7. Italy Diabetic Retinopathy Market
- 6.3.7.1. Market Size and Forecast, By Type
- 6.3.7.2. Market Size and Forecast, By Treatment Type
- 6.3.8. Spain Diabetic Retinopathy Market
- 6.3.8.1. Market Size and Forecast, By Type
- 6.3.8.2. Market Size and Forecast, By Treatment Type
- 6.3.9. U.K Diabetic Retinopathy Market
- 6.3.9.1. Market Size and Forecast, By Type
- 6.3.9.2. Market Size and Forecast, By Treatment Type
- 6.3.10. Rest Of Europe Diabetic Retinopathy Market
- 6.3.10.1. Market Size and Forecast, By Type
- 6.3.10.2. Market Size and Forecast, By Treatment Type
- 6.4.Asia-Pacific
- 6.4.1. Key Market Trends and Opportunities
- 6.4.2. Market Size and Forecast, By Type
- 6.4.3. Market Size and Forecast, By Treatment Type
- 6.4.4. Market Size and Forecast, By Country
- 6.4.5. China Diabetic Retinopathy Market
- 6.4.5.1. Market Size and Forecast, By Type
- 6.4.5.2. Market Size and Forecast, By Treatment Type
- 6.4.6. Japan Diabetic Retinopathy Market
- 6.4.6.1. Market Size and Forecast, By Type
- 6.4.6.2. Market Size and Forecast, By Treatment Type
- 6.4.7. India Diabetic Retinopathy Market
- 6.4.7.1. Market Size and Forecast, By Type
- 6.4.7.2. Market Size and Forecast, By Treatment Type
- 6.4.8. South Korea Diabetic Retinopathy Market
- 6.4.8.1. Market Size and Forecast, By Type
- 6.4.8.2. Market Size and Forecast, By Treatment Type
- 6.4.9. Australia Diabetic Retinopathy Market
- 6.4.9.1. Market Size and Forecast, By Type
- 6.4.9.2. Market Size and Forecast, By Treatment Type
- 6.4.10. Rest of Asia Pacific Diabetic Retinopathy Market
- 6.4.10.1. Market Size and Forecast, By Type
- 6.4.10.2. Market Size and Forecast, By Treatment Type
- 6.5.LAMEA
- 6.5.1. Key Market Trends and Opportunities
- 6.5.2. Market Size and Forecast, By Type
- 6.5.3. Market Size and Forecast, By Treatment Type
- 6.5.4. Market Size and Forecast, By Country
- 6.5.5. Brazil Diabetic Retinopathy Market
- 6.5.5.1. Market Size and Forecast, By Type
- 6.5.5.2. Market Size and Forecast, By Treatment Type
- 6.5.6. South Africa, Diabetic Retinopathy Market
- 6.5.6.1. Market Size and Forecast, By Type
- 6.5.6.2. Market Size and Forecast, By Treatment Type
- 6.5.7. Saudi Arabia Diabetic Retinopathy Market
- 6.5.7.1. Market Size and Forecast, By Type
- 6.5.7.2. Market Size and Forecast, By Treatment Type
- 6.5.8. Rest of LAMEA Diabetic Retinopathy Market
- 6.5.8.1. Market Size and Forecast, By Type
- 6.5.8.2. Market Size and Forecast, By Treatment Type
- CHAPTER 7:COMPANY PROFILES
- 7.1. Alimera Sciences, Inc.
- 7.1.1.Company Overview
- 7.1.2.Key Executives
- 7.1.3.Company snapshot
- 7.1.4.Operating business segments
- 7.1.5.Product portfolio
- 7.1.6.Business Performance
- 7.1.7.Key Strategic Moves and Developments
- 7.2. Abbvie Inc
- 7.2.1.Company Overview
- 7.2.2.Key Executives
- 7.2.3.Company snapshot
- 7.2.4.Operating business segments
- 7.2.5.Product portfolio
- 7.2.6.Business Performance
- 7.2.7.Key Strategic Moves and Developments
- 7.3. Ampio Pharmaceuticals
- 7.3.1.Company Overview
- 7.3.2.Key Executives
- 7.3.3.Company snapshot
- 7.3.4.Operating business segments
- 7.3.5.Product portfolio
- 7.3.6.Business Performance
- 7.3.7.Key Strategic Moves and Developments
- 7.4. Bayer AG
- 7.4.1.Company Overview
- 7.4.2.Key Executives
- 7.4.3.Company snapshot
- 7.4.4.Operating business segments
- 7.4.5.Product portfolio
- 7.4.6.Business Performance
- 7.4.7.Key Strategic Moves and Developments
- 7.5. KOWA CO.,LTD.
- 7.5.1.Company Overview
- 7.5.2.Key Executives
- 7.5.3.Company snapshot
- 7.5.4.Operating business segments
- 7.5.5.Product portfolio
- 7.5.6.Business Performance
- 7.5.7.Key Strategic Moves and Developments
- 7.6. Novartis AG
- 7.6.1.Company Overview
- 7.6.2.Key Executives
- 7.6.3.Company snapshot
- 7.6.4.Operating business segments
- 7.6.5.Product portfolio
- 7.6.6.Business Performance
- 7.6.7.Key Strategic Moves and Developments
- 7.7. Pfizer Inc.
- 7.7.1.Company Overview
- 7.7.2.Key Executives
- 7.7.3.Company snapshot
- 7.7.4.Operating business segments
- 7.7.5.Product portfolio
- 7.7.6.Business Performance
- 7.7.7.Key Strategic Moves and Developments
- 7.8. Regeneron Pharmaceuticals Inc.
- 7.8.1.Company Overview
- 7.8.2.Key Executives
- 7.8.3.Company snapshot
- 7.8.4.Operating business segments
- 7.8.5.Product portfolio
- 7.8.6.Business Performance
- 7.8.7.Key Strategic Moves and Developments
- 7.9. F-Hoffmann-La Roche Ltd
- 7.9.1.Company Overview
- 7.9.2.Key Executives
- 7.9.3.Company snapshot
- 7.9.4.Operating business segments
- 7.9.5.Product portfolio
- 7.9.6.Business Performance
- 7.9.7.Key Strategic Moves and Developments
- 7.10. Valeant Pharmaceuticals
- 7.10.1.Company Overview
- 7.10.2.Key Executives
- 7.10.3.Company snapshot
- 7.10.4.Operating business segments
- 7.10.5.Product portfolio
- 7.10.6.Business Performance
- 7.10.7.Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1.GLOBAL DIABETIC RETINOPATHY MARKET, BY TYPE, 2020-2030 ($MILLION)
- TABLE 2.GLOBAL DIABETIC RETINOPATHY MARKET FOR PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2020-2030 ($MILLION)
- TABLE 3.GLOBAL DIABETIC RETINOPATHY MARKET FOR DIABETIC MACULAR EDEMA (DME), BY REGION, 2020-2030 ($MILLION)
- TABLE 4.GLOBAL DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 5.GLOBAL DIABETIC RETINOPATHY MARKET FOR ANTI VEGF DRUG, BY REGION, 2020-2030 ($MILLION)
- TABLE 6.GLOBAL DIABETIC RETINOPATHY MARKET FOR STEROID IMPLANTS, BY REGION, 2020-2030 ($MILLION)
- TABLE 7.GLOBAL DIABETIC RETINOPATHY MARKET FOR LASER SURGERIES, BY REGION, 2020-2030 ($MILLION)
- TABLE 8.GLOBAL DIABETIC RETINOPATHY MARKET FOR VITRECTOMY, BY REGION, 2020-2030 ($MILLION)
- TABLE 9.GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION, 2020-2030 ($MILLION)
- TABLE 10.NORTH AMERICA DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 11.NORTH AMERICA DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 12.UNITED STATES DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 13.UNITED STATES DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 14.CANADA DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 15.CANADA DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 16.MEXICO DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 17.MEXICO DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 18.EUROPE DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 19.EUROPE DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 20.FRANCE DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 21.FRANCE DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 22.GERMANY DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 23.GERMANY DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 24.ITALY DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 25.ITALY DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 26.SPAIN DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 27.SPAIN DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 28.UNITED KINGDOM DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 29.UNITED KINGDOM DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 30.REST OF EUROPE DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 31.REST OF EUROPE DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 32.ASIA-PACIFIC DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 33.ASIA-PACIFIC DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 34.CHINA DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 35.CHINA DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 36.JAPAN DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 37.JAPAN DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 38.INDIA DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 39.INDIA DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 40.SOUTH KOREA DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 41.SOUTH KOREA DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 42.AUSTRALIA DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 43.AUSTRALIA DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 44.REST OF ASIA PACIFIC DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 45.REST OF ASIA PACIFIC DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 46.LAMEA DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 47.LAMEA DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 48.BRAZIL DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 49.BRAZIL DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 50.SOUTH AFRICA, DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 51.SOUTH AFRICA, DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 52.SAUDI ARABIA DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 53.SAUDI ARABIA DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 54.REST OF LAMEA DIABETIC RETINOPATHY, BY TYPE, 2020-2030 ($MILLION)
- TABLE 55.REST OF LAMEA DIABETIC RETINOPATHY, BY TREATMENT TYPE, 2020-2030 ($MILLION)
- TABLE 56.ALIMERA SCIENCES, INC.: KEY EXECUTIVES
- TABLE 57.ALIMERA SCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 58.ALIMERA SCIENCES, INC.: OPERATING SEGMENTS
- TABLE 59.ALIMERA SCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 60.ALIMERA SCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 61.ABBVIE INC: KEY EXECUTIVES
- TABLE 62.ABBVIE INC: COMPANY SNAPSHOT
- TABLE 63.ABBVIE INC: OPERATING SEGMENTS
- TABLE 64.ABBVIE INC: PRODUCT PORTFOLIO
- TABLE 65.ABBVIE INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 66.AMPIO PHARMACEUTICALS: KEY EXECUTIVES
- TABLE 67.AMPIO PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 68.AMPIO PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 69.AMPIO PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 70.AMPIO PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 71.BAYER AG: KEY EXECUTIVES
- TABLE 72.BAYER AG: COMPANY SNAPSHOT
- TABLE 73.BAYER AG: OPERATING SEGMENTS
- TABLE 74.BAYER AG: PRODUCT PORTFOLIO
- TABLE 75.BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 76.KOWA CO.,LTD.: KEY EXECUTIVES
- TABLE 77.KOWA CO.,LTD.: COMPANY SNAPSHOT
- TABLE 78.KOWA CO.,LTD.: OPERATING SEGMENTS
- TABLE 79.KOWA CO.,LTD.: PRODUCT PORTFOLIO
- TABLE 80.KOWA CO.,LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 81.NOVARTIS AG: KEY EXECUTIVES
- TABLE 82.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 83.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 84.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 85.NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 86.PFIZER INC.: KEY EXECUTIVES
- TABLE 87.PFIZER INC.: COMPANY SNAPSHOT
- TABLE 88.PFIZER INC.: OPERATING SEGMENTS
- TABLE 89.PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 90.PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 91.REGENERON PHARMACEUTICALS INC.: KEY EXECUTIVES
- TABLE 92.REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
- TABLE 93.REGENERON PHARMACEUTICALS INC.: OPERATING SEGMENTS
- TABLE 94.REGENERON PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
- TABLE 95.REGENERON PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 96.F-HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES
- TABLE 97.F-HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
- TABLE 98.F-HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
- TABLE 99.F-HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
- TABLE 100.F-HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 101.VALEANT PHARMACEUTICALS: KEY EXECUTIVES
- TABLE 102.VALEANT PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 103.VALEANT PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 104.VALEANT PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 105.VALEANT PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1.GLOBAL DIABETIC RETINOPATHY MARKET SEGMENTATION
- FIGURE 2.GLOBAL DIABETIC RETINOPATHY MARKET
- FIGURE 3.SEGMENTATION DIABETIC RETINOPATHY MARKET
- FIGURE 4.TOP INVESTMENT POCKET IN DIABETIC RETINOPATHY MARKET
- FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
- FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
- FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
- FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
- FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
- FIGURE 11.LOW THREAT OF SUBSTITUTION
- FIGURE 12.HIGH COMPETITIVE RIVALRY
- FIGURE 13.TOP PLAYER POSITIONING, 2020
- FIGURE 14.MARKET SHARE ANALYSIS, 2020
- FIGURE 15.RESTRAINTS AND DRIVERS: DIABETIC RETINOPATHY MARKET
- FIGURE 16.DIABETIC RETINOPATHY MARKET SEGMENTATION, BY TYPE
- FIGURE 17.DIABETIC RETINOPATHY MARKET FOR PROLIFERATIVE DIABETIC RETINOPATHY, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 18.DIABETIC RETINOPATHY MARKET FOR DIABETIC MACULAR EDEMA (DME), BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 19.DIABETIC RETINOPATHY MARKET SEGMENTATION, BY TREATMENT TYPE
- FIGURE 20.DIABETIC RETINOPATHY MARKET FOR ANTI VEGF DRUG, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 21.DIABETIC RETINOPATHY MARKET FOR STEROID IMPLANTS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 22.DIABETIC RETINOPATHY MARKET FOR LASER SURGERIES, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 23.DIABETIC RETINOPATHY MARKET FOR VITRECTOMY, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 24.ALIMERA SCIENCES, INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 25.ALIMERA SCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 26.ALIMERA SCIENCES, INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 27.ABBVIE INC: NET SALES, 2018-2020 ($MILLION)
- FIGURE 28.ABBVIE INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 29.ABBVIE INC: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 30.AMPIO PHARMACEUTICALS: NET SALES, 2018-2020 ($MILLION)
- FIGURE 31.AMPIO PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 32.AMPIO PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 33.BAYER AG: NET SALES, 2018-2020 ($MILLION)
- FIGURE 34.BAYER AG: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 35.BAYER AG: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 36.KOWA CO.,LTD.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 37.KOWA CO.,LTD.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 38.KOWA CO.,LTD.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 39.NOVARTIS AG: NET SALES, 2018-2020 ($MILLION)
- FIGURE 40.NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 41.NOVARTIS AG: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 42.PFIZER INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 43.PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 44.PFIZER INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 45.REGENERON PHARMACEUTICALS INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 46.REGENERON PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 47.REGENERON PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 48.F-HOFFMANN-LA ROCHE LTD: NET SALES, 2018-2020 ($MILLION)
- FIGURE 49.F-HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 50.F-HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 51.VALEANT PHARMACEUTICALS: NET SALES, 2018-2020 ($MILLION)
- FIGURE 52.VALEANT PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 53.VALEANT PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2020 (%)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook